Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: An ex vivo and drug resistance molecular markers study

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Fall, Bécaye ^a   Pascual, Aurélie ^b,c,d   Sarr, Fatoumata D ^e   Wurtz, Nathalie ^b,c   Richard, Vincent ^e   Baret, Eric ^b,c,d   Diémé, Yaya ^a   Briolant, Sébastien ^b,c   Bercion, Raymond ^a   Wade, Boubacar ^a   Tall, Adama ^e   Pradines, Bruno ^a,b,c,d  

^a HÔPITAL PRINCIPAL DE DAKAR   (Senegal)

^b INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^c AIX MARSEILLE UNIVERSITÉ   (France)

^d Centre National de Reference du Paludisme   (France)

^e INSTITUT PASTEUR DE DAKAR   (Senegal)

Author keywords

Anti malarial; in vitro; Malaria; Molecular marker; Plasmodium falciparum; Resistance; Senegal

Indexed keywords

ANTIMALARIAL AGENT; BENFLUMETOL; CHLOROQUINE; DEETHYLAMODIAQUINE; DIHYDROARTEMISININ; DOXYCYCLINE; DRUG METABOLITE; LACTATE DEHYDROGENASE; MEFLOQUINE; MOLECULAR MARKER; QUININE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CODON; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; IC 50; IN VITRO STUDY; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; PRESCHOOL CHILD; SCHOOL CHILD; SENEGAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; CELL SURVIVAL; CHILD; CHILD, PRESCHOOL; DNA, PROTOZOAN; DRUG RESISTANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; MUTATION, MISSENSE; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; POLYMORPHISM, GENETIC; PROTOZOAN PROTEINS; SENEGAL; YOUNG ADULT;

EID: 84875081693     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-107     Document Type: Article

References (92)

1. Antimalarial drug resistance. Le Bras J, Musset L, Clain J, Med Mal Infect 2006 36 401 405 10.1016/j.medmal.2006.05.005 16854546 (Pubitemid 44425394)
2. Preventing antimalarial drug resistance through combinations. White NJ, Drug. Resist Updat 2001 1 3 9
3. Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial. Ndiaye JLA, Faye B, Gueye A, Tine R, Ndiaye D, Tchania C, Ndiaye I, Barry A, Cisse B, Lameyre V, Gaye O, Malar J 2011 10 237 10.1186/1475-2875-10-237 21838909
4. Major reduction in anti-malarial drug consumption in Senegal after nation-wide introduction of malaria rapid diagnostic tests. Thiam S, Thior M, Faye B, Diouf ML, Diouf MB, Diallo I, Fall FB, Ndiaye JL, Albertini A, Lee E, Jorgensen P, Gaye O, Bell D, Plos One 2011 6 18419 10.1371/journal.pone.0018419
5. Conditions of malaria transmission in Dakar from 2007 to 2010. Gadiaga L, Machault V, Pagès F, Gaye A, Jarjaval F, Godefroy L, Cissé B, Lacaux JP, Sokhna C, Trape JF, Rogier C, Malar J 2011 10 312 10.1186/1475-2875-10-312 22018223
6. IgG responses to the gSG6-P1 salivary peptide for evaluating human exposure to Anopheles bites in urban areas of Dakar. Drame PM, Machault V, Diallo A, Cornélie S, Poinsignon A, Lalou R, Sembène M, Dos Santos S, Rogier C, Pagès F, Le Hesran JY, Remoué F, Senegal. Malar J 2012 11 72 10.1186/1475-2875-11-72
7. Asymptomatic carriage of Plasmodium in urban Dakar: the risk of malaria should not be underestimated. Diallo A, Ndam NT, Moussiliou A, Dos Santos S, Ndonky A, Borderon M, Oliveau S, Lalou R, Le Hesran JY, Plos One 2012 7 31300 10.1371/journal.pone.0031300
8. Ministère de la Santé et de la Prévention, Rapport sur la morbidité et la mortalité palustre au Sénégal en 2008 Dakar: Programme National de Lutte contre le Paludisme 2010 http://www.pnlp.sn/UserFiles/File/donnee.pdf
9. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LMB, Sidhu ABS, Naudé B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE, Mol Cell 2000 6 861 871 10.1016/S1097-2765(05)00077-8 11090624
10. Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Zolg JW, Plitt JR, Chen GX, Palmer S, Mol Biochem Parasitol 1989 36 253 262 10.1016/0166-6851(89)90173-4 2677719 (Pubitemid 19222399)
11. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilisation. Wang P, Read M, Sims PF, Hyde JE, Mol Microbiol 1997 23 979 986 10.1046/j.1365-2958.1997.2821646.x 9076734 (Pubitemid 27096733)
12. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the Western border of Thailand. Price RN, Cassar C, Brockman A, Duraisingh M, van Vugt M, White NJ, Nosten F, Krishna S, Antimicrob Agents Chemother 1999 43 2943 2949 10582887
13. Chloroquine resistance reversal agents as promising antimalarial drugs. Henry M, Alibert S, Orlandi-Pradines E, Bogreau H, Fusai T, Rogier C, Barbe J, Pradines B, Curr Drug Targets 2006 7 935 948 10.2174/138945006778019372 16918322 (Pubitemid 44227578)
14. Inhibition of efflux of quinolines as new therapeutic strategy in malaria. Henry M, Alibert S, Rogier C, Barbe J, Pradines B, Curr Top Med Chem 2008 8 563 578 10.2174/156802608783955593 18473883 (Pubitemid 351982580)
15. New haplotypes of the Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene among chloroquine-resistant parasite isolates. Nagesha HS, Casey GJ, Rieckmann H, Fryauff DJ, Laksana BS, Reeder JC, Maguire JD, Baird J, Am J Trop Med Hyg 2003 68 398 402 12875286 (Pubitemid 38230637)
16. Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents. Johnson DJ, Fidock DA, Mungthin M, Lakshmanan V, Sidhu AB, Bray PG, Ward SA, Mol Cell 2004 15 867 877 10.1016/j.molcel.2004.09.012 15383277 (Pubitemid 39277984)
17. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P, Malar J 2009 8 89 10.1186/1475-2875-8-89 19413906
18. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mbenu EK, Cowman AF, Winstanley PA, Watkins WM, Nzila AM, Trends Parasitol 2001 17 582 588 10.1016/S1471-4922(01)02085-2 11756042 (Pubitemid 34088118)
19. Inhibition of Plasmodium falciparum dihydropteroate synthetase and growth in vitro by sulfa drugs. Zhang Y, Meshnick SR, Antimicrob Agents Chemother 1991 35 267 271 10.1128/AAC.35.2.267 2024960
20. Molecular epidemiology of malaria in Yaoundé, Cameroon. III. Analysis of chloroquine resistance and point mutations in the multidrug resistance 1 (pfmdr 1) gene of Plasmodium falciparum. Basco LK, Ringwald P, Am J Trop Med Hyg 1998 59 577 581 9790433 (Pubitemid 28480714)
21. Evidence for selection for the tyrosine-86 allele of the pfmdr 1 gene of Plasmodium falciparum by chloroquine and amodiaquine. Duraisingh MT, Drakeley CJ, Muller O, Bailey R, Snounou G, Targett GA, Greenwood BM, Warhurst DC, Parasitology 1997 114 205 211 10.1017/S0031182096008487 9075340 (Pubitemid 27135229)
22. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance. Foote SJ, Kyle DE, Martin RK, Oduola AM, Forsyth K, Kemp DJ, Cowman AF, Nature 1990 345 255 258 10.1038/345255a0 2185424 (Pubitemid 20163056)
23. Plasmodium falciparum: in vitro chloroquine susceptibility and allele-specific PCR detection of Pfmdr1 Asn86Tyr polymorphism in Lambarene, Gabon. Grobusch MP, Adagu IS, Kremsner PG, Warhurst DC, Parasitology 1998 116 211 217 10.1017/S0031182097002266 9550213 (Pubitemid 28129372)
24. Plasmodim falciparum: Molecular characterization of multi drug-resistant Cambodian isolates. Basco LK, de Pecoulas PE, Le Bras J, Wilson EN, Exp Parasitol 1996 82 97 103 8617353 (Pubitemid 26161931)
25. The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea. Marfurt J, Muller I, Sie A, Oa O, Reeder JC, Smith TA, Beck HP, Genton B, Malar J 2008 7 61 10.1186/1475-2875-7-61 18423045 (Pubitemid 351678131)
26. The pfmdr1 gene of Plasmodium falciparum confers cellular resistance to antimalarial drugs in yeast cells. Ruetz S, Delling U, Brault M, Schurr E, Gros P, Proc Natl Acad Sci USA 1996 93 9942 9947 10.1073/pnas.93.18.9942 8790436 (Pubitemid 26296714)
27. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF, Nature 2000 403 906 909 10.1038/35002615 10706290 (Pubitemid 30130994)
28. Lack of prediction of mefloquine and mefloquine-artesunate treatment outcome by mutations in the Plasmodium falciparum multidrug resistance 1 (pfmdr1) gene for P. falciparum malaria in Peru. Pillai DR, Hijar G, Montoya I, Marquino W, Ruebush TK, Wrongsrichanalai C, Kain KC, Am J Trop Med Hyg 2003 68 107 110 12557835 (Pubitemid 38234857)
29. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC, Mol Biochem Parasitol 2000 108 13 23 10.1016/S0166-6851(00)00201-2 10802315 (Pubitemid 30236312)
30. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum. Duraisingh MT, Roper C, Walliker D, Warhurst DC, Mol Microbiol 2000 36 955 961 10.1046/j.1365-2958.2000.01914.x 10844681 (Pubitemid 30326539)
31. Synchronization of Plasmodium falciparum erythrocytic stages in culture. Lambros C, Vanderberg JP, J Parasitol 1979 65 418 420 10.2307/3280287 383936 (Pubitemid 10222999)
32. Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas. Bogreau H, Renaud F, Bouchiba H, Durand P, Assi SB, Henry MC, Garnotel E, Pradines B, Fusai T, Wade B, Adehossi E, Parola P, Kamil MO, Puijalon O, Rogier C, Am J Trop Med Hyg 2006 74 953 959 16760503 (Pubitemid 351627399)
33. Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates. Henry M, Diallo I, Bordes J, Ka S, Pradines B, Diatta B, M'Baye PS, Sane M, Thiam M, Gueye PM, Wade B, Touze JE, Debonne JM, Rogier C, Fusai T, Am J Trop Med Hyg 2006 75 146 151 16837722 (Pubitemid 351627584)
34. Use of the atmospheric generators for capnophilic bacteria Genbag CO§ssub§2§esub§® for the evaluation of in vitro Plasmodium falciparum susceptibility to standard anti-malarial drugs. Pascual A, Basco LK, Baret E, Amalvict R, Travers D, Rogier C, Pradines B, Malar J 2011 10 8 10.1186/1475-2875-10-8 21235757
35. Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from Africa using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Kaddouri H, Nakache S, Houzé S, Mentré F, Le Bras J, Antimicrob Agents Chemother 2006 50 3343 3349 10.1128/AAC.00367-06 17005815 (Pubitemid 44527508)
36. Online analysis of in vitro resistance to antimalarial drugs through nonlinear regression. Le Nagard H, Vincent C, Mentré F, Le Bras J, Comput Methods Programs Biomed 2011 104 10 18 10.1016/j.cmpb.2010.08.003 20828858
37. Relationship between the Pfcrt T76 and the Pfmdr-1 Y86 mutations in Plasmodium falciparum and in vitro/in vivo chloroquine resistance in Burkina Faso, West Africa. Tinto H, Ouédraogo JB, Erhart A, van Overmeir C, Dujardin JC, van Marck E, Guiguemdé TR, D'Alessandro U, Infect Genet Evol 2003 3 287 292 10.1016/j.meegid.2003.08.002 14636690 (Pubitemid 37408279)
38. Molecular epidemiology of malaria in Cameroon.X. Evaluation of Pfmdr1 mutations as genetic markers for resistance to amino alcohols and artemisinin derivatives. Am J. Basco LK, Ringwald P, Trop Med Hyg 2002 66 667 671 (Pubitemid 35005825)
39. Antimalarial drug susceptibility and point mutations associated with resistance in 248 Plasmodium falciparum isolates imported from Comoros to Marseille. Parola P, Pradines B, Simon F, Carlotti MP, Minodier P, Ranjeva MP, Badiaga S, Bertaux L, Delmont J, Morillon M, Silai R, Brouqui P, Parzy D, Am J Trop Med Hyg 2007 77 431 437 17827355 (Pubitemid 351844314)
40. Ex vivo susceptibility of Plasmodium isolates from Dakar, Senegal, to seven standard anti-malarial drugs. Fall B, Diawara S, Sow K, Baret E, Diatta B, Fall KB, Mbate PS, Fall F, Diémé Y, Rogier C, Wade B, Bercion R, Pradines B, Malar J 2011 10 310 10.1186/1475-2875-10-310 22014157
41. Resistance of Plasmodium falciparum field isolates to in vitro artemether and point mutations of the SERCA-type PfATPase6. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala MT, Bouchier C, Esterre P, Fandeur T, Mercereau-Puijalon O, Lancet 2005 366 1960 1963 10.1016/S0140-6736(05)67787-2 16325698 (Pubitemid 41713986)
42. Sensibilité in vitro de 85 isolats de Plasmodium falciparum au Sénégal. Pradines B, Rogier C, Fusai T, Tall A, Doury JC, Med Trop 1996 56 141 145 (Pubitemid 26264211)
43. In vitro activities of ferrochloroquine against 55 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Pradines B, Tall A, Rogier C, Spiegel A, Mosnier J, Marrama L, Fusai T, Millet P, Panconi E, Trape JF, Parzy D, Trop Med Int Health 2002 7 265 270 10.1046/j.1365-3156.2002.00848.x 11903989 (Pubitemid 34264379)
44. In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti. Pradines B, Mabika Mamfoumbi M, Tall A, Sokhna C, Koeck JL, Fusai T, Mosnier J, Czarnecki E, Spiegel A, Trape JF, Kombila M, Rogier C, Antimicrob Agents Chemother 2006 50 3225 3226 10.1128/AAC.00777-06 16940138 (Pubitemid 44396447)
45. Sénégal et paludisme. Echec prophylactique vrai de la méfloquine. Gari-Toussaint M, Pradines B, Mondain V, Keundjian A, Dellamonica P, Le Fichoux Y, Presse Med 2002 31 1136 12162100 (Pubitemid 34760712)
46. Susceptibility of Plasmodium falciparum strains to mefloquine in an urban area in Senegal. Hatin I, Trape JF, Legros F, Bauchet J, Le Bras J, Bull World Health Organ 1992 70 363 367 1638665
47. Tests in vivo de chimiosensibilite de Plasmodium falciparum à la chloroquine au Sénégal: évolution de la résistance et estimation de l'efficacité thérapeutique. Sokhna C, Molez JF, Ndiaye P, Sane B, Trape JF, Bull Soc Pathol Exot 1997 90 83 89 9289259
48. In vitro activity of artemether against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial drugs. Pradines B, Rogier C, Fusai T, Tall A, Trape JF, Doury JC, Am J Trop Med Hyg 1998 58 354 357 9546418 (Pubitemid 28160760)
49. In vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial agents. Pradines B, Tall A, Parzy D, Spiegel A, Fusai T, Hienne R, Trape JF, Doury JC, J Antimicrob Chemother 1998 42 333 339 10.1093/jac/42.3.333 9786473 (Pubitemid 28442447)
50. In vitro activity of iron-binding compounds against Senegalese isolates of Plasmodium falciparum. Pradines B, Tall A, Ramiandrasoa F, Spiegel A, Sokhna C, Fusai T, Mosnier J, Daries W, Trape JF, Kunesch G, Parzy D, Rogier C, J Antimicrob Chemother 2006 57 1093 1099 10.1093/jac/dkl117 16595639 (Pubitemid 44644410)
51. Short report: an non-radioactive DAPI-based high-throughput in vitro assay to assess Plasmodium falciparum responsiveness to antimalarials-Increased sensitivity of P. falciparum to chloroquine in Senegal. Ndiaye D, Patel V, Demas A, LeRoux M, Ndir O, Mboup S, Clardy J, Lakshmanan V, Daily JP, Wirth DF, Am J Trop Med Hyg 2010 82 228 230 10.4269/ajtmh.2010.09-0470 20133997
52. A molecular marker for chloroquine-resistant falciparum malaria. Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, N Engl J Med 2001 344 257 263 10.1056/NEJM200101253440403 11172152 (Pubitemid 32108530)
53. Accumulation of CIEVT Pfcrt allele of Plasmodium falciparum in placenta of pregnant women living in an urban area of Dakar, Senegal. Niang M, Marrama L, Ekala MT, Gaye A, Tall A, Ndiaye JL, Sarr D, Dangou JM, Lehesran JY, Bouchier C, Mercereau-Puijalon O, Jambou R, J Antimicrob Chemother 2008 62 921 928 10.1093/jac/dkn299 18682531
54. In vitro chloroquine susceptibility and PCR analysis of pfcrt and pfmdr1 polymorphisms in Plasmodium falciparum isolates from Senegal. Thomas SM, Ndir O, Dieng T, Mboup S, Wypij D, Maguire JH, Wirth DF, Am J Trop Med Hyg 2002 66 474 480 12201579
55. In vivo and in vitro analysis of chloroquine resistance in Plasmodium falciparum isolates from Senegal. Sarr O, Myrick A, Daily J, Diop BM, Dieng T, Ndir O, Salif Sow P, Mboup S, Wirth DF, Parasitol Res 2005 97 136 140 10.1007/s00436-005-1406-7 15986248 (Pubitemid 41225080)
56. Mutations in PfCRT K76T do no correlate with sulfadoxine-pyrimethamine- amodiaquine failure in Pikine. Sarr O, Ahouidi AD, Ly O, Daily JP, Ndiaye D, Ndir O, Mboup S, Wirth DF, Parasitol Res 2008 103 765 769 10.1007/s00436-008- 1038-9 18523801
57. High prevalence of Plasmodium falciparum pfcrt K76T mutation in pregnant women taking chloroquine prophylaxis in Senegal. Bertin G, Ndam NT, Jafari-Guemouri S, Fievet N, Renart E, Sow S, Le Hesran JY, Deloron P, J Antimicrob Chemother 2005 55 788 791 10.1093/jac/dki097 15814601 (Pubitemid 40691864)
58. Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar. Wurtz N, Fall B, Pascual A, Diawara S, Sow K, Baret E, Diatta B, Fall KB, Mbaye PS, Fall F, Diémé Y, Rogier C, Bercion R, Briolant S, Wade B, Pradines B, Senegal. Malar J 2012 11 197 10.1186/1475-2875-11-197
59. Assessment of the molecular marker of Plasmodium falciparum chloroquine resistance (Pfcrt) in Senegal after several years of chloroquine withdrawal. Ndiaye M, Faye B, Tine R, Ndiaye JL, Lo A, Abiola A, Dieng Y, Ndiaye D, Hallett R, Alifrangis M, Gaye O, Am J Trop Med Hyg 2012 87 640 645 10.4269/ajtmh.2012. 11-0709 22927495
60. Evolution of the pfcrt T76 and pfmdr1 Y86 markers and chloroquine susceptibility 8 years after cessation of chloroquine use in Pikine, Senegal. Ly O, Gueye PE, Deme AB, Dieng T, Badiane AS, Ahouidi AD, Diallo M, Bei AK, Wirth DF, Mboup S, Sarr O, Parasitol Res 2012 111 1541 1546 10.1007/s00436-012-2994-7 22706959
61. Antimalarial drug use in general populations of tropical Africa. Gardella F, Assi S, Simon F, Bogreau H, Eggelte T, Ba F, Foumane V, Henry MC, Traore Kientega P, Basco L, Trape JF, Lalou R, Martelloni M, Desbordes M, Baragatti M, Briolant S, Almeras L, Pradines B, Fusai T, Rogier C, Malar J 2008 7 124 10.1186/1475-2875-7-124 18611279
62. Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data. Frosch AEP, Venkatesan M, Laufer MK, Malar J 2011 10 116 10.1186/1475-2875-10-116 21554692
63. Ministère de la Santé et de la Prévention Médicale, Enquête nationale sur le paludisme au Sénégal 2006 2007 http://www.measuredhs.com/pubs/pdf/MIS1/MIS1.pdf 17703338
64. Ministère de la Santé et de la Prévention Médicale, Enquête nationale sur le paludisme au Sénégal 2008-2009 2009 http://www.measuredhs.com/publications/ publication-MIS5-MIS-Final-Reports.cfm 17703338
65. Remergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine in Malawi. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimdé AA, Kouriba B, Taylor TE, Plowe CV, J Infect Dis 2003 187 1870 1875 10.1086/375419 12792863 (Pubitemid 36724485)
66. Return of chloroquine antimalarial efficacy in Malawi. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV, N Engl J Med 2006 355 1959 1966 10.1056/NEJMoa062032 17093247 (Pubitemid 44708015)
67. Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial use. Noranate N, Durand R, Tall A, Marrama L, Spiegel A, Sokhna C, Pradines B, Cojean S, Guillotte M, Bischoff E, Ekala MT, Bouchier C, Fandeur T, Ariey F, Patarapotikul J, Le Bras J, Trape JF, Rogier C, Mercereau-Puijalon O, Plos One 2007 1 139
68. Plasmodium falciparum in vitro susceptibility to antimalarial drugs in Casamance (Southwestern Senegal) during the first 5 years of routine use of artesunate-amodiaquine. Agnamey P, Brasseur P, de Pecoulas E, Vaillant M, Olliaro P, Antimicrob Agents Chemother 2006 50 1531 1534 10.1128/AAC.50.4.1531- 1534.2006 16569876
69. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Bjorkman A, Infect Gen Evol 2006 6 309 314 10.1016/j.meegid.2005.09.001 (Pubitemid 43785813)
70. Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda. Nsobya SL, Dokomajilar C, Joloba M, Dorsey G, Rosenthal PJ, Antimicrob Agents Chemother 2007 51 3023 3025 10.1128/AAC.00012-07 17562798 (Pubitemid 47206253)
71. Polymorphisms in the pfcrt and pfmdr1 genes of Plasmodium falciparum and in vitro susceptibility to amodiaquine and desethylamodiaquine. Echeverry DF, Holmgren G, Murillo C, Higuita JC, Gil JP, Osorio L, Am J Trop Med Hyg 2007 77 1034 1038 18165517 (Pubitemid 351837788)
72. Selection of pfmdr1 and pfcrt alleles in amodiaquine treatment failure in north-western Burkina Faso. Danquah I, Coulibaly B, Meissner P, Petruschke I, Muller O, Mockenhaupt FP, Acta Trop 2010 114 63 33 10.1016/j.actatropica.2009. 12.008 20060374
73. Amodiaquine remains effective for treating ucomplicated malaria in West and Central Africa. Brasseur P, Guiguemde R, Diallo S, Guiyedi V, Kombila M, Ringwald P, Olliaro P, Trans R Soc Trop Med Hyg 1999 93 645 650 10.1016/S0035-9203(99)90083-4 10717757 (Pubitemid 30015796)
74. Randomized, comparative study of the efficacy and safety of artesunate plus amodiaquine, administered as a single daily intake versus two daily intakes in the treatment of uncomplicated falciparum malaria. Ndiaye JL, Faye B, Diouf AM, Kuété T, Cisse M, Seck PA, Brasseur P, Same-Ekobo A, Lameyre V, Gaye O, Malar J 2008 7 16 10.1186/1475-2875-7-16 18205945 (Pubitemid 351328665)
75. Randomized, multicentre assessment of the efficacy and safety of ASAQ-a fixed dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, Randrianasolo L, Ratsimbasoa A, Forlemu D, Ama Moor V, Traore A, Dicko Y, Dara N, Lameyre V, Diallo M, Djimdé A, Same-Ekobo A, Gaye O, Malar J 2009 8 125 10.1186/1475-2875-8-125 19505304
76. Artemisinin resistance in Plasmodium falciparum malaria. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwrong M, Chotivanish K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ, N Engl J Med 2009 361 455 467 10.1056/NEJMoa0808859 19641202
77. Evidence of artemisinin-resistant malaria in western Cambodia. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, N Engl J Med 2008 359 2619 2620 10.1056/NEJMc0805011 19064625
78. The rationale and plan for creating a World Antimalarial Resistance Network (WARN). Sibley CH, Barnes KI, Plowe CV, Malar J 2007 6 118 10.1186/1475-2875-6-118 17822531 (Pubitemid 47525010)
79. A network to monitor antimalarial drug resistance: a plan for moving forward. Sibley CH, Barnes KI, Watkins WM, Plowe CV, Trends Parasitol 2008 24 43 48 10.1016/j.pt.2007.09.008 18042432
80. In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Pradines B, Tall A, Fusai T, Spiegel A, Hienne R, Rogier C, Trape JF, Le Bras J, Parzy D, Antimicrob Agents Chemother 1999 43 418 420 9925550 (Pubitemid 29079190)
81. Decreased sensitivity to chloroquine and quinine of some Plasmodium falciparum strains from Senegal in September 1984. Brandicourt O, Druilhe P, Diouf F, Brasseur P, Turk P, Danis M, Am J Trop Med Hyg 1986 35 717 721 3524287 (Pubitemid 16072232)
82. Quinine resistant falciparum malaria acquired in east Africa. Jelinek T, Schelbert P, Loscher T, Eichenlaub D, Trop Med Parasitol 1995 46 38 40 7631126
83. Genetic confirmation of quinine-resistant Plasmodium falciparum malaria followed by postmalaria neurological syndrome in a traveler from Mozambique. Palmieri F, Petrosillo N, Paglia MG, Conte A, Goletti D, Pucillo LP, Menegon M, Sannella A, Severini C, Majori G, J Clin Microbiol 2004 42 5424 5426 10.1128/JCM.42.11.5424-5426.2004 15528762 (Pubitemid 39506275)
84. Quinine-resistant malaria in traveler returning from Senegal, 2007. Pradines B, Pistone T, Ezzedine K, Briolant S, Bertaux L, Receveur MC, Parzy D, Millet P, Rogier C, Malvy D, Emerg Infect Dis 2010 16 546 548 10.3201/eid1603.091669 20202443
85. Antibiotics for prophylaxis of Plasmodium falciparum infections: in vitro activity of doxycycline against Senegalese isolates. Pradines B, Spiegel A, Rogier C, Tall A, Mosnier J, Fusai T, Trape JF, Parzy D, Am J Trop Med Hyg 2000 62 82 85 10761729 (Pubitemid 30180355)
86. Multinormal in vitro distribution model suitable for the distribution of Plasmodium falciparum chemosusceptibility to doxycycline. Briolant S, Baragatti M, Parola P, Simon F, Tall A, Sokhna C, Hovette P, Mabika Mamfoumbi M, Koeck JL, Delmont J, Spiegel A, Castello J, Gardair JP, Trape JF, Kombila M, Minodier P, Fusai T, Rogier C, Pradines B, Antimicrob Agents Chemother 2009 53 688 695 10.1128/AAC.00546-08 19047651
87. In vitro activities of antibiotics against Plasmodium falciparum are inhibited by iron. Pradines B, Rogier C, Fusai T, Mosnier J, Daries W, Baret E, Parzy D, Antimicrob Agents Chemother 2001 45 1746 1750 10.1128/AAC.45.6.1746- 1750.2001 11353621 (Pubitemid 32466344)
88. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Senegal. Ndiaye D, Dailly JP, Sarr O, Ndir O, Gaye O, Mboup S, Wirth DF, Trop Med Int Health 2005 10 1176 1179 10.1111/j.1365-3156.2005.01506.x 16262743 (Pubitemid 41641196)
89. Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. Cissé B, Cairns M, Faye E, NDiaye O, Faye B, Cames C, Cheng Y, NDiaye M, Colle Lo A, Simondon K, Trape JF, Faye O, NDiaye JL, Gaye O, Greenwood B, Milligan P, Plos One 2009 4 7164 10.1371/journal.pone.0007164
90. Prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxine-pyrimethamine during the intermittent preventive treatment in infants coupled with expanded program immunization in Senegal. Faye B, Ndiaye M, Ndiaye JL, Annie A, Tine RC, Collé Lo A, Ndiaye M, Sow D, De Sousa A, Gaye O, Parasitol Res 2011 109 133 138 10.1007/s00436-010-2236-9 21207062
91. A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. Sokhna C, Cissé B, Ba EH, Milligan P, Hallett R, Sutherland C, Gaye O, Boulanger D, Simondon K, Simondon F, Targett G, Lines J, Greenwood B, Trape JF, Plos One 2008 3 1471 10.1371/journal.pone.0001471 (Pubitemid 351796321)
92. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomized, placebo-controlled, double-blind trial. Cissé B, Sokhna C, Boulanger D, Milet J, Ba EH, Richardson K, Hallett R, Sutherland C, Simondon K, Simondon F, Alexander N, Gaye O, Targett G, Lines J, Greenwood B, Trappe JF, Lancet 2006 367 659 667 10.1016/S0140-6736(06)68264-0 16503464 (Pubitemid 43289156)